Dr Mariusz Skwarczynski has research experience in organic and medicinal chemistry, lipo/peptide and macromolecule synthesis, self-assembly, and other techniques involved in nanoparticle formation, as well as liposomal and polymer-based delivery systems for medical agents. They have also applied knowledge in vaccine and antibiotic design, their characterisation, and in vitro and in vivo evaluation, and has developed several new vaccine candidates and their delivery systems. Dr Skwarczynski was also involved in the development of an epimerisation-free method for the synthesis of novel isopeptide building blocks, which was used for the synthesis of difficult sequences containing peptides, and in studying the amyloid hypothesis in Alzheimer’s disease. These units were commercialised by Merck-Novabiochem. In Australia, they are involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria and cancer (mainly HPV-related), along with antibiotics against multidrug resistant bacteria.